Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2024 04:00 ET | Source: SiSaf Ltd

SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild to Moderate Alopecia Areata

Positive topline results in a Phase II clinical trial of a licensee’s alopecia treatment using the ProSilic® variant of SiSaf’s Bio-Courier® delivery technology Formulation of the small molecule drug...
September 18, 2023 04:00 ET | Source: SiSaf Ltd

Peer-Reviewed Publication of Positive Preclinical Data of SiSaf’s SIS-ADO2 siRNA Program to Treat Rare Genetic Bone Disorder Osteopetrosis

GUILDFORD, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA therapeutics company, is pleased to announce the publication in the peer-reviewed journal Molecular Therapy Nucleic...
July 13, 2023 04:00 ET | Source: SiSaf Ltd

SiSaf Appoints Nikos Tzagkarakis in the New Role of Chief A.I. Officer

GUILDFORD, England, July 13, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd announces that it has appointed Nikos Tzagkarakis in the newly created role of Chief A.I....
May 15, 2023 03:00 ET | Source: SiSaf Ltd

FDA Grants SiSaf’s Innovative siRNA Therapy SIS-101-ADO Orphan Drug Designation and Rare Pediatric Disease Designation for the Treatment of Autosomal Dominant Osteopetrosis

GUILDFORD, England, May 15, 2023 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that SIS-101-ADO, its siRNA therapeutic for patients with Autosomal Dominant...
April 05, 2023 03:00 ET | Source: SiSaf Ltd

SiSaf Appoints Dr. Richard Goodfellow to Board of Directors

GUILDFORD, England, April 05, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announced that it has appointed Dr. Richard Goodfellow to its Board of Directors. ...
March 02, 2023 04:00 ET | Source: SiSaf Ltd

SiSaf and the University of Leipzig Partner to Develop Bio-Courier Targeted miRNA for the Treatment of Pancreatic Cancer

GUILDFORD, United Kingdom, March 02, 2023 (GLOBE NEWSWIRE) -- RNA delivery and therapeutics company SiSaf Ltd today announces its collaboration with the University of Leipzig, Germany, to develop...
December 18, 2019 09:21 ET | Source: SiSaf Ltd

SiSaf Establishes Strategic Partnership with Avellino Labs USA to Co-Develop Non-Viral, Topical Gene Therapies for Corneal Dystrophy

LONDON, Dec. 18, 2019 (GLOBE NEWSWIRE) -- SiSaf Ltd, pioneers of Bio-Courier® technology, today announced it has entered into a strategic collaboration with Avellino Labs USA, Inc., a leader in...